| Active substance | empagliflozin |
| Holder | Boehringer Ingelheim International GmbH |
| Status | closed |
| Indication | treatment of adult patients with heart failure with preserved ejection fraction (ejection fraction >40%) |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Last update |
04/04/2023 |